elearning

Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Bookmark and Share

Bone Metastases

This module is based on the latest scientific evidence for treating bone metastatic disease and aims to support physicians in delivering exceptional standards of patient care. Covering the prevalence of bone metastatic disease, diagnosis, imaging techniques and treatment options. 

This module was published on the 7th September 2017.

Bone Metastases
Module
English
1 CME Points

Target audience

This education is aimed at consultants and/or attending physicians in the treatment of bone metastases.

Learning objectives

By the end of this module, you should be able to understand:

  • The prevalence of skeletal metastases in different solid tumours.
  • The definition of skeletal related events.
  • Imaging techniques for the diagnosis of bone metastases.
  • Serum and urine markers of bone resorption.
  • Mechanism of action of bisphosphonates and denosumab.

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Amgen.

Support

Production of this module was funded by an unrestricted grant from Amgen.